Table 1.
Meningococcal vaccination programs.
| Vaccination Campaign |
Year: Casesa (Incidence Rate)b |
|||||
|---|---|---|---|---|---|---|
| Serogroup | Location | Year Implemented | Age Group | Vaccine | Prevaccination | Postvaccination |
| A | Burkina Faso78,117 (epidemic) |
2010 | 1–29 y | MenAfriVac | 2009: 1994 | 2010: 430 2011: 111 2012: 49 2013: 4 |
| Chad89 (epidemic) |
2011 (N'Djamena regions) | 1–29 y | MenAfriVac |
N'Djamena regions 2010: 27 |
N'Djamena regions 2011: 45 2012: 0 2013: 0 |
|
| 2012 (Rest of Chad) |
Rest of Chad 2010: 28 2011: 110 |
Rest of Chad 2012: 59 2013: 1 |
||||
| B | United Kingdom71 | 2014 | ≥2 mo | Bexsero | 2012–2013: 595 2013–2014: 424 |
2014–2015: 418 2015–2016: 444 |
| Cuba31 (epidemic) | 1989 | 3.5 mo to <20 y | VA–Mengoc–BC | 1984: (14.1) 1985: (13.5) 1986: (11.0) 1987: (8.8) 1988: (8.8) |
1989: (6.5) 1990: (4.2) 1991: (2.4) 1992: (1.4) 1993: (0.8) 1994: (0.8) |
|
| Norway32 | 2004 | MenBvac | 1999–2000: 83 (1.9) | NA | ||
| France118 | 2006 | 1–19 y | MenBvac |
Dieppe region 2003–2006: 28 (8.6) |
Dieppe region 2006–2008:c 9 (4.9) 2008–2010: 3 (1.5) |
|
|
Rest of Seine–Maritime region 2003–2006: 19 (0.5) |
Rest of Seine–Maritime region) 2006–2008: 15 (0.7) 2008–2010: 9 (0.4) |
|||||
| New Zealand33,34,95 | 2004 | <20 y | MeNZB | 2001: 285 (24.7) 2002: 211 (18.1) 2003: 187 (15.8) |
2004: 144 (12.1) 2005: 80 (6.7) 2006: 47 (3.9) 2007: 37 (3.1) 2008: 31 (2.6) |
|
| United States38,41,111 | 2013–2016 | 10–25 y | Trumenba Bexsero |
Colleges/Universities Princeton, 2013: 9 Santa Barbara, 2013: 5 Providence College, 2015: 2 University of Oregon, 2015: 7 Santa Clara, 2016: 3 Rutgers, 2016: 2 |
||
| C | Quebec City, Canada46 (Epidemic) |
2001 | 2 mo to 20 y | Menjugate | 2001: 58 (7.84) | 2002: 27 (3.63) |
| United Kingdom50 (Epidemic) |
1999 | 2 mo to 17 y | MCCs (Meningitec, Menjugate, NeisVac-C) | 1998/1999d 537 | 2000–2001d: 103 | |
| Netherlands60 | 2002 | 14 mo (1-dose series) 1–18 y (catch-up) |
MCC | 2001: 276 | 2003: 42 | |
| Spain119 | 2000 | 2 mo to <6 y | MCCs (Meningitec, Menjugate, NeisVac-C) | 1999: 268 (7.04) | 2000–2001: 56 (1.46) 2001–2002: 49 (1.26) 2002–2003: 42 (1.08) |
|
| ACWY | United States69 | 2005 | 11–12 y Increased risk: |
MCV4 |
Serogroup C 2004: 27 (0.07) |
Serogroup C 2005: 25 (0.07) 2006: 29 (0.08) |
| 11–55 y 2–10 y >55 y |
MCV4 MPSV4 MPSV4 |
Serogroup Y 2004: 31 (0.08) |
Serogroup Y 2005: 39 (0.11) 2006: 42 (0.12) |
|||
| 2007 | 11–18 y | MCV4 |
Serogroup C 2006: 29 (0.08) |
Serogroup C 2007: 36 (0.10) 2008: 38 (0.10) |
||
|
Serogroup Y 2006: 42 (0.12) |
Serogroup Y 2007: 45 (0.12) 2008: 31 (0.08) |
|||||
| 2010 | 11–12 + 16 y | MCV4 |
Serogroup C 2009: 28 (0.07) |
Serogroup C 2010: 17 (0.04) 2011: 19 (0.05) |
||
|
Serogroup Y 2009: 37 (0.10) |
Serogroup Y 2010: 27 (0.07) 2011: 27 (0.07) |
|||||
NA = not available.
a
Total cases for all age groups.
b
The campaign was targeted at children <6 years, but in 3 of 19 regions, this age range was extended up to adolescence.
c
Cases collected during the primary vaccination phase.
d
Incidence rate is per 100,000